Skip to main content
. 2023 May 16;213(2):252–264. doi: 10.1093/cei/uxad055

Table 1.

Top 20 significant transcripts upregulated and top 20 down-regulated by narsoplimab in TA-TMA patient plasma-exposed MVEC

Upregulated LogFC F Downregulated LogFC F
RNU6-678P 5.12 2.74 SLC14A1 −2.00 0.80
MIR4766 4.91 3.75 C2orf66 −1.26 1.08
MIR589 4.16 5.05 ZNF521 −0.42 2.51
SNORD101 1.99 1.15 WFS1 −0.35 2.01
MIR6813 1.98 0.68 SRD5A3-AS1 −0.33 0.14
SERPINB2 1.90 7.81 KRT7 −0.30 0.86
MIR4477B 1.70 3.38 IL1R1 −0.28 1.44
CHAC1 1.64 9.59 FBLN5 −0.27 3.73
MT1L 1.60 3.94 SOX18 −0.25 1.67
TM4SF18 1.53 34.21 ACAN −0.21 0.36
ASPM 1.43 22.57 RAB11FIP1 −0.21 1.21
CA2 1.42 7.41 JUP −0.20 2.51
MIR762 1.41 2.03 PPP1R10 −0.20 1.15
PSAT1 1.35 25.88 ALPK3 −0.20 2.48
SPC25 1.33 8.45 HOXD9 −0.20 2.00
SNCB 1.33 11.87 MIR5587 −0.20 0.04
TNFSF15 1.32 12.53 TMEM204 −0.19 1.60
ESM1 1.26 13.92 DOCK9 −0.18 1.16
TTK 1.26 8.77 BICD1 −0.18 1.53
TNFSF18 1.23 9.34 LOX −0.18 0.70